You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMoexipril
Accession NumberDB00691  (APRD01120)
TypeSmall Molecule
GroupsApproved
DescriptionMoexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.
Structure
Thumb
Synonyms
Moexipril
Moexiprilum
Uniretic
Univasc
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Univasctablet, film coated7.5 mg/1oralUCB, Inc.1995-07-15Not applicableUs
Univasctablet, film coated15 mg/1oralUCB, Inc.1995-07-152016-02-25Us
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Moexipril Hydrochloridetablet, film coated15 mg/1oralGlenmark Pharmaceuticals Inc., Usa2010-12-31Not applicableUs
Moexipril Hydrochloridetablet, film coated7.5 mg/1oralTeva Pharmaceuticals USA Inc2003-05-08Not applicableUs
Moexipril Hydrochloridetablet7.5 mg/1oralApotex Corp.2008-06-09Not applicableUs
Moexipril Hydrochloridetablet, film coated7.5 mg/1oralGlenmark Pharmaceuticals Inc., Usa2010-12-31Not applicableUs
Moexipril Hydrochloridetablet, film coated15 mg/1oralTeva Pharmaceuticals USA Inc2003-05-08Not applicableUs
Moexipril Hydrochloridetablet15 mg/1oralApotex Corp.2008-06-09Not applicableUs
Moexipril Hydrochloridetablet, film coated7.5 mg/1oralAvera Mc Kennan Hospital2015-08-10Not applicableUs
Moexipril Hydrochloridetablet15 mg/1oralPhysicians Total Care, Inc.2004-04-27Not applicableUs
Moexipril Hydrochloridetablet, film coated7.5 mg/1oralCarilion Materials Management2003-05-08Not applicableUs
Moexipril Hydrochloridetablet7.5 mg/1oralPhysicians Total Care, Inc.2008-08-14Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Moexipril Hydrochloride and HydrochlorothiazideTeva Pharmaceuticals USA Inc
Salts
Name/CASStructureProperties
Moexipril Hydrochloride
Thumb
  • InChI Key: JXRAXHBVZQZSIC-JKVLGAQCSA-N
  • Monoisotopic Mass: 534.213279191
  • Average Mass: 535.029
DBSALT000504
Categories
UNIIWT87C52TJZ
CAS number103775-10-6
WeightAverage: 498.5681
Monoisotopic: 498.236601452
Chemical FormulaC27H34N2O7
InChI KeyInChIKey=UWWDHYUMIORJTA-HSQYWUDLSA-N
InChI
InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1
IUPAC Name
(3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[[email protected]]1C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPeptides
Alternative Parents
Substituents
  • Alpha peptide
  • Alpha-amino acid ester
  • Alpha-amino acid amide
  • Tetrahydroisoquinoline
  • Phenylpropylamine
  • Alpha-amino acid or derivatives
  • N-substituted-alpha-amino acid
  • Anisole
  • Aralkylamine
  • Fatty acid ester
  • Alkyl aryl ether
  • Fatty acyl
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of hypertension.
PharmacodynamicsMoexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.
Mechanism of actionMoexipril is a prodrug for moexiprilat, which inhibits ACE in humans and animals. The mechanism through which moexiprilat lowers blood pressure is believed to be primarily inhibition of ACE activity. ACE is a peptidyl dipeptidase that catalyzes the conversion of the inactive decapeptide angiotensin I to the vasoconstrictor substance angiotensin II. Angiotensin II is a potent peripheral vasoconstrictor that also stimulates aldosterone secretion by the adrenal cortex and provides negative feedback on renin secretion. ACE is identical to kininase II, an enzyme that degrades bradykinin, an endothelium-dependent vasodilator. Moexiprilat is about 1000 times as potent as moexipril in inhibiting ACE and kininase II. Inhibition of ACE results in decreased angiotensin II formation, leading to decreased vasoconstriction, increased plasma renin activity, and decreased aldosterone secretion. The latter results in diuresis and natriuresis and a small increase in serum potassium concentration (mean increases of about 0.25 mEq/L were seen when moexipril was used alone). Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of moexipril remains to be elucidated. Although the principal mechanism of moexipril in blood pressure reduction is believed to be through the renin-angiotensin-aldosterone system, ACE inhibitors have some effect on blood pressure even in apparent low-renin hypertension.
Related Articles
AbsorptionMoexipril is incompletely absorbed, with bioavailability as moexiprilat of about 13% compared to intravenous (I.V.) moexipril (both measuring the metabolite moexiprilat), and is markedly affected by food, which reduces Cmax and AUC by about 70% and 40%, respectively, after the ingestion of a low-fat breakfast or by 80% and 50%, respectively, after the ingestion of a high-fat breakfast.
Volume of distribution
  • 183 L
Protein bindingMoexiprilat is approxomately 50% protein bound.
Metabolism

Rapidly converted to moexiprilat, the active metabolite. Conversion to the active metabolite is thought to require carboxyesterases and is likely to occur in organs or tissues, other than the gastrointestinal tract, in which carboxyesterases occur. The liver is thought to be one site of conversion, but not the primary site.

SubstrateEnzymesProduct
Moexipril
Not Available
MoexiprilatDetails
Route of eliminationMoexiprilat undergoes renal elimination.
Half lifeMoexipril elimination half-life is approximately 1 hour. Moexiprilat elimination half-life is 2 to 9 hours.
Clearance
  • 441 mL/min
ToxicityHuman overdoses of moexipril have not been reported. In case reports of overdoses with other ACE inhibitors, hypotension has been the principal adverse effect noted. Single oral doses of 2 g/kg moexipril were associated with significant lethality in mice. Rats, however, tolerated single oral doses of up to 3 g/kg. Common adverse effects include cough, dizziness, diarrhea, flu syndrome, fatigue, pharyngitis, flushing, rash, and myalgia
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Moexipril Metabolism PathwayDrug metabolismSMP00595
Moexipril Action PathwayDrug actionSMP00151
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5775
Blood Brain Barrier-0.9022
Caco-2 permeable-0.7313
P-glycoprotein substrateSubstrate0.9085
P-glycoprotein inhibitor IInhibitor0.5919
P-glycoprotein inhibitor IIInhibitor0.8157
Renal organic cation transporterNon-inhibitor0.8146
CYP450 2C9 substrateNon-substrate0.8588
CYP450 2D6 substrateNon-substrate0.8369
CYP450 3A4 substrateSubstrate0.7014
CYP450 1A2 substrateNon-inhibitor0.8205
CYP450 2C9 inhibitorNon-inhibitor0.5961
CYP450 2D6 inhibitorNon-inhibitor0.8261
CYP450 2C19 inhibitorNon-inhibitor0.6592
CYP450 3A4 inhibitorNon-inhibitor0.5935
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6861
Ames testNon AMES toxic0.8358
CarcinogenicityNon-carcinogens0.9378
BiodegradationNot ready biodegradable0.9762
Rat acute toxicity2.5131 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9715
hERG inhibition (predictor II)Inhibitor0.8751
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apotex inc
  • Glenmark generics ltd
  • Paddock laboratories inc
  • Teva pharmaceuticals usa inc
  • Schwarz pharma inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral15 mg/1
Tabletoral7.5 mg/1
Tablet, film coatedoral
Tablet, film coatedoral15 mg/1
Tablet, film coatedoral7.5 mg/1
Prices
Unit descriptionCostUnit
Univasc 15 mg tablet2.44USD tablet
Univasc 7.5 mg tablet2.13USD tablet
Moexipril hcl 15 mg tablet1.48USD tablet
Moexipril hcl 7.5 mg tablet1.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySoluble (about 10% weight-to-volume) in distilled water at room temperature as HCl salt.Not Available
logP2.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00585 mg/mLALOGPS
logP1.52ALOGPS
logP1.5ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)3.46ChemAxon
pKa (Strongest Basic)5.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area114.4 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity132.88 m3·mol-1ChemAxon
Polarizability53.55 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Asmar R, Sayegh F, Tracz W, Hlawaty M, Olszowska M, Jourde M, Vincent M, Goujoun B, Maldonado J: Reversal of left ventricular hypertrophy with the ACE inhibitor moexipril in patients with essential hypertension. Acta Cardiol. 2002 Feb;57(1):31-2. [PubMed:11918132 ]
  2. Blacher J, Raison J, Amah G, Schiemann AL, Stimpel M, Safar ME: Increased arterial distensibility in postmenopausal hypertensive women with and without hormone replacement therapy after acute administration of the ACE inhibitor moexipril. Cardiovasc Drugs Ther. 1998 Sep;12(4):409-14. [PubMed:9825188 ]
  3. Brogden RN, Wiseman LR: Moexipril. A review of its use in the management of essential hypertension. Drugs. 1998 Jun;55(6):845-60. [PubMed:9617599 ]
  4. Cawello W, Boekens H, Waitzinger J, Miller U: Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition. Int J Clin Pharmacol Ther. 2002 Jan;40(1):9-17. [PubMed:11837383 ]
  5. Chrysant SG, Chrysant GS: Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol. 2004 Aug;44(8):827-36. [PubMed:15286086 ]
  6. Chrysant SG, Chrysant GS: Pharmacological profile and clinical use of moexipril. Expert Rev Cardiovasc Ther. 2003 Sep;1(3):345-52. [PubMed:15030263 ]
  7. Chrysant GS, Nguyen PK: Moexipril and left ventricular hypertrophy. Vasc Health Risk Manag. 2007;3(1):23-30. [PubMed:17583172 ]
  8. Grass GM, Morehead WT: Evidence for site-specific absorption of a novel ACE inhibitor. Pharm Res. 1989 Sep;6(9):759-65. [PubMed:2554270 ]
  9. Kalasz H, Petroianu G, Tekes K, Klebovich I, Ludanyi K, Gulyas Z: Metabolism of moexipril to moexiprilat: determination of in vitro metabolism using HPLC-ES-MS. Med Chem. 2007 Jan;3(1):101-6. [PubMed:17266629 ]
  10. Persson B, Stimpel M: Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients. Eur J Clin Pharmacol. 1996;50(4):259-64. [PubMed:8803515 ]
  11. Spinar J, Vitovec J: MORE--MOexipril and REgression of left ventricle hypertrophy in combination therapy A multicentric open label clinical trial. Int J Cardiol. 2005 Apr 20;100(2):199-206. [PubMed:15823625 ]
  12. Stimpel M, Koch B, Oparil S: Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide). Cardiology. 1998 May;89(4):271-6. [PubMed:9643274 ]
  13. White CM: Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy. 1998 May-Jun;18(3):588-99. [PubMed:9620109 ]
  14. White WB, Whelton A, Fox AA, Stimpel M, Kaihlanen PM: Tricenter assessment of the efficacy of the ACE inhibitor, moexipril, by ambulatory blood pressure monitoring. J Clin Pharmacol. 1995 Mar;35(3):233-8. [PubMed:7608310 ]
External Links
ATC CodesC09AA13C09BA13
AHFS Codes
  • 24:32.04
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Moexipril.
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Moexipril.
AcebutololMoexipril may increase the hypotensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Moexipril is combined with Aceclofenac.
AcetazolamideThe risk or severity of adverse effects can be increased when Moexipril is combined with Acetazolamide.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Moexipril is combined with Acetylsalicylic acid.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Moexipril.
AdapaleneThe risk or severity of adverse effects can be increased when Moexipril is combined with Adapalene.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Moexipril.
AlfuzosinAlfuzosin may increase the hypotensive activities of Moexipril.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Moexipril.
AliskirenMoexipril may increase the hypotensive activities of Aliskiren.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Moexipril.
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Moexipril.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Moexipril.
AlprenololMoexipril may increase the hypotensive activities of Alprenolol.
AmbrisentanMoexipril may increase the hypotensive activities of Ambrisentan.
AmifostineMoexipril may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Moexipril.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Moexipril.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Moexipril.
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Moexipril.
AmiodaroneMoexipril may increase the QTc-prolonging activities of Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Moexipril.
AmlodipineAmlodipine may increase the hypotensive activities of Moexipril.
AmobarbitalAmobarbital may increase the hypotensive activities of Moexipril.
Amyl NitriteThe risk or severity of adverse effects can be increased when Moexipril is combined with Amyl Nitrite.
AnagrelideMoexipril may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe risk or severity of adverse effects can be increased when Moexipril is combined with Antipyrine.
ApraclonidineThe risk or severity of adverse effects can be increased when Moexipril is combined with Apraclonidine.
ApremilastThe risk or severity of adverse effects can be increased when Moexipril is combined with Apremilast.
AprotininAprotinin may decrease the antihypertensive activities of Moexipril.
ArdeparinArdeparin may increase the hyperkalemic activities of Moexipril.
AripiprazoleAripiprazole may increase the hypotensive activities of Moexipril.
Arsenic trioxideMoexipril may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherMoexipril may increase the QTc-prolonging activities of Artemether.
AsenapineMoexipril may increase the QTc-prolonging activities of Asenapine.
AtenololAtenolol may increase the hypotensive activities of Moexipril.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Moexipril.
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Moexipril.
AzapropazoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Azapropazone.
AzathioprineMoexipril may increase the myelosuppressive activities of Azathioprine.
AzelastineThe risk or severity of adverse effects can be increased when Moexipril is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Moexipril is combined with Azilsartan medoxomil.
AzithromycinMoexipril may increase the QTc-prolonging activities of Azithromycin.
BalsalazideThe risk or severity of adverse effects can be increased when Moexipril is combined with Balsalazide.
BarbitalBarbital may increase the hypotensive activities of Moexipril.
BedaquilineMoexipril may increase the QTc-prolonging activities of Bedaquiline.
BemiparinBemiparin may increase the hyperkalemic activities of Moexipril.
BenazeprilBenazepril may increase the hypotensive activities of Moexipril.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Moexipril.
BenmoxinBenmoxin may increase the hypotensive activities of Moexipril.
BenoxaprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Benoxaprofen.
BepridilMoexipril may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Moexipril.
BethanidineBethanidine may increase the hypotensive activities of Moexipril.
BimatoprostMoexipril may increase the hypotensive activities of Bimatoprost.
BisoprololBisoprolol may increase the hypotensive activities of Moexipril.
BoceprevirThe serum concentration of Moexipril can be decreased when it is combined with Boceprevir.
BosentanBosentan may increase the hypotensive activities of Moexipril.
BretyliumMoexipril may increase the hypotensive activities of Bretylium.
BrimonidineMoexipril may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Moexipril.
BromfenacThe risk or severity of adverse effects can be increased when Moexipril is combined with Bromfenac.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Moexipril.
BumetanideThe risk or severity of adverse effects can be increased when Moexipril is combined with Bumetanide.
BupranololMoexipril may increase the hypotensive activities of Bupranolol.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Moexipril.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Moexipril.
CanagliflozinThe risk or severity of adverse effects can be increased when Moexipril is combined with Canagliflozin.
CandesartanMoexipril may increase the hypotensive activities of Candesartan.
CandoxatrilCandoxatril may increase the hypotensive activities of Moexipril.
CaptoprilMoexipril may increase the hypotensive activities of Captopril.
CarbamazepineThe metabolism of Moexipril can be increased when combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypotensive activities of Moexipril.
CarprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Moexipril.
CarvedilolMoexipril may increase the hypotensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Moexipril is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Moexipril is combined with Celecoxib.
CeliprololMoexipril may increase the hypotensive activities of Celiprolol.
CeritinibMoexipril may increase the QTc-prolonging activities of Ceritinib.
CertoparinCertoparin may increase the hyperkalemic activities of Moexipril.
ChloroquineThe risk or severity of adverse effects can be increased when Moexipril is combined with Chloroquine.
ChlorothiazideMoexipril may increase the hypotensive activities of Chlorothiazide.
ChlorpromazineMoexipril may increase the QTc-prolonging activities of Chlorpromazine.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Moexipril.
CilazaprilMoexipril may increase the hypotensive activities of Cilazapril.
CiprofloxacinMoexipril may increase the arrhythmogenic activities of Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Moexipril.
CitalopramMoexipril may increase the QTc-prolonging activities of Citalopram.
ClarithromycinMoexipril may increase the QTc-prolonging activities of Clarithromycin.
ClevidipineThe risk or severity of adverse effects can be increased when Moexipril is combined with Clevidipine.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Moexipril.
ClonidineClonidine may increase the hypotensive activities of Moexipril.
ClonixinThe risk or severity of adverse effects can be increased when Moexipril is combined with Clonixin.
ClozapineMoexipril may increase the QTc-prolonging activities of Clozapine.
CrizotinibMoexipril may increase the QTc-prolonging activities of Crizotinib.
CryptenamineMoexipril may increase the hypotensive activities of Cryptenamine.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Moexipril.
CyclophosphamideThe risk or severity of adverse effects can be increased when Moexipril is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Moexipril.
CyclothiazideCyclothiazide may increase the hypotensive activities of Moexipril.
D-LimoneneThe risk or severity of adverse effects can be increased when Moexipril is combined with D-Limonene.
DalteparinDalteparin may increase the hyperkalemic activities of Moexipril.
DapagliflozinThe risk or severity of adverse effects can be increased when Moexipril is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Moexipril.
DebrisoquinMoexipril may increase the hypotensive activities of Debrisoquin.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Moexipril.
DeserpidineMoexipril may increase the hypotensive activities of Deserpidine.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Moexipril.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Moexipril.
DiazoxideDiazoxide may increase the hypotensive activities of Moexipril.
DiclofenacThe risk or severity of adverse effects can be increased when Moexipril is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Moexipril is combined with Diclofenamide.
DiflunisalThe risk or severity of adverse effects can be increased when Moexipril is combined with Diflunisal.
DiflunisalDiflunisal may decrease the antihypertensive activities of Moexipril.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Moexipril.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Moexipril.
DiltiazemDiltiazem may increase the hypotensive activities of Moexipril.
DinutuximabThe risk or severity of adverse effects can be increased when Moexipril is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Moexipril is combined with Dipyridamole.
DisopyramideMoexipril may increase the QTc-prolonging activities of Disopyramide.
DofetilideMoexipril may increase the QTc-prolonging activities of Dofetilide.
DolasetronMoexipril may increase the QTc-prolonging activities of Dolasetron.
DomperidoneMoexipril may increase the QTc-prolonging activities of Domperidone.
DorzolamideMoexipril may increase the hypotensive activities of Dorzolamide.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Moexipril.
DoxazosinDoxazosin may increase the hypotensive activities of Moexipril.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Moexipril.
DronedaroneMoexipril may increase the QTc-prolonging activities of Dronedarone.
DroperidolMoexipril may increase the QTc-prolonging activities of Droperidol.
DrospirenoneMoexipril may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Moexipril is combined with Droxicam.
DuloxetineMoexipril may increase the orthostatic hypotensive activities of Duloxetine.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Moexipril.
EfonidipineMoexipril may increase the hypotensive activities of Efonidipine.
EliglustatMoexipril may increase the QTc-prolonging activities of Eliglustat.
EmpagliflozinThe risk or severity of adverse effects can be increased when Moexipril is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Moexipril.
EnalaprilatMoexipril may increase the hypotensive activities of Enalaprilat.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Moexipril.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Moexipril.
EpirizoleThe risk or severity of adverse effects can be increased when Moexipril is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Moexipril.
EplerenoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Eplerenone.
EpoprostenolMoexipril may increase the hypotensive activities of Epoprostenol.
EprosartanMoexipril may increase the hypotensive activities of Eprosartan.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Moexipril.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Moexipril.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Moexipril.
ErythromycinMoexipril may increase the QTc-prolonging activities of Erythromycin.
EscitalopramMoexipril may increase the QTc-prolonging activities of Escitalopram.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Moexipril.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Moexipril.
Etacrynic acidThe risk or severity of adverse effects can be increased when Moexipril is combined with Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Moexipril is combined with Etanercept.
EtodolacThe risk or severity of adverse effects can be increased when Moexipril is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Moexipril is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Moexipril is combined with Etoricoxib.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Moexipril.
Evening primrose oilThe risk or severity of adverse effects can be increased when Moexipril is combined with Evening primrose oil.
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Moexipril.
exisulindThe risk or severity of adverse effects can be increased when Moexipril is combined with exisulind.
FelodipineMoexipril may increase the hypotensive activities of Felodipine.
FenbufenThe risk or severity of adverse effects can be increased when Moexipril is combined with Fenbufen.
FenoldopamMoexipril may increase the hypotensive activities of Fenoldopam.
FenoprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Fenoprofen.
FlecainideMoexipril may increase the QTc-prolonging activities of Flecainide.
FloctafenineThe risk or severity of adverse effects can be increased when Moexipril is combined with Floctafenine.
FlunixinThe risk or severity of adverse effects can be increased when Moexipril is combined with Flunixin.
FluoxetineMoexipril may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolMoexipril may increase the QTc-prolonging activities of Flupentixol.
FlurbiprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Flurbiprofen.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Moexipril.
FosinoprilFosinopril may increase the hypotensive activities of Moexipril.
FurazolidoneFurazolidone may increase the hypotensive activities of Moexipril.
FurosemideThe risk or severity of adverse effects can be increased when Moexipril is combined with Furosemide.
Gadobenic acidMoexipril may increase the QTc-prolonging activities of Gadobenic acid.
GarlicThe serum concentration of Moexipril can be decreased when it is combined with Garlic.
GemifloxacinMoexipril may increase the QTc-prolonging activities of Gemifloxacin.
GoserelinMoexipril may increase the QTc-prolonging activities of Goserelin.
GranisetronMoexipril may increase the QTc-prolonging activities of Granisetron.
GuanabenzGuanabenz may increase the hypotensive activities of Moexipril.
GuanadrelGuanadrel may increase the hypotensive activities of Moexipril.
GuanethidineMoexipril may increase the hypotensive activities of Guanethidine.
GuanfacineMoexipril may increase the hypotensive activities of Guanfacine.
HaloperidolMoexipril may increase the QTc-prolonging activities of Haloperidol.
HeparinHeparin may increase the hyperkalemic activities of Moexipril.
HexamethoniumMoexipril may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Moexipril.
HMPL-004The risk or severity of adverse effects can be increased when Moexipril is combined with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Moexipril.
HydralazineMoexipril may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideMoexipril may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideMoexipril may increase the hypotensive activities of Hydroflumethiazide.
IbuprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Moexipril is combined with Ibuproxam.
IbutilideMoexipril may increase the QTc-prolonging activities of Ibutilide.
IcatibantIcatibant may decrease the antihypertensive activities of Moexipril.
IcatibantThe risk or severity of adverse effects can be increased when Moexipril is combined with Icatibant.
IloperidoneMoexipril may increase the QTc-prolonging activities of Iloperidone.
IloprostIloprost may increase the hypotensive activities of Moexipril.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Moexipril.
IndapamideMoexipril may increase the hypotensive activities of Indapamide.
IndenololMoexipril may increase the hypotensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Moexipril is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Indoprofen.
IndoraminMoexipril may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Moexipril.
IproniazidIproniazid may increase the hypotensive activities of Moexipril.
IrbesartanMoexipril may increase the hypotensive activities of Irbesartan.
IronThe risk or severity of adverse effects can be increased when Moexipril is combined with Iron.
Iron DextranThe risk or severity of adverse effects can be increased when Moexipril is combined with Iron Dextran.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Moexipril.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Moexipril is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Moexipril is combined with Isosorbide Mononitrate.
IsoxicamThe risk or severity of adverse effects can be increased when Moexipril is combined with Isoxicam.
IsoxsuprineThe risk or severity of adverse effects can be increased when Moexipril is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Moexipril.
KebuzoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Moexipril is combined with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Moexipril.
LacidipineMoexipril may increase the hypotensive activities of Lacidipine.
Lanthanum carbonateThe serum concentration of Moexipril can be decreased when it is combined with Lanthanum carbonate.
LatanoprostLatanoprost may increase the hypotensive activities of Moexipril.
LeflunomideThe risk or severity of adverse effects can be increased when Moexipril is combined with Leflunomide.
LenvatinibMoexipril may increase the QTc-prolonging activities of Lenvatinib.
LercanidipineLercanidipine may increase the hypotensive activities of Moexipril.
LeuprolideMoexipril may increase the QTc-prolonging activities of Leuprolide.
LevobunololThe risk or severity of adverse effects can be increased when Moexipril is combined with Levobunolol.
LevodopaMoexipril may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinMoexipril may increase the QTc-prolonging activities of Levofloxacin.
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Moexipril.
LisinoprilMoexipril may increase the hypotensive activities of Lisinopril.
LithiumThe serum concentration of Lithium can be increased when it is combined with Moexipril.
LofexidineMoexipril may increase the hypotensive activities of Lofexidine.
LopinavirMoexipril may increase the QTc-prolonging activities of Lopinavir.
LornoxicamThe risk or severity of adverse effects can be increased when Moexipril is combined with Lornoxicam.
LosartanLosartan may increase the hypotensive activities of Moexipril.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Moexipril.
LoxoprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Loxoprofen.
LumefantrineMoexipril may increase the QTc-prolonging activities of Lumefantrine.
LumiracoxibThe risk or severity of adverse effects can be increased when Moexipril is combined with Lumiracoxib.
MacitentanMoexipril may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Moexipril is combined with Magnesium salicylate.
ManidipineMoexipril may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Moexipril is combined with Mannitol.
MasoprocolThe risk or severity of adverse effects can be increased when Moexipril is combined with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Moexipril.
MecamylamineMecamylamine may increase the hypotensive activities of Moexipril.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Moexipril is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Moexipril is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Moexipril is combined with Meloxicam.
MesalazineThe risk or severity of adverse effects can be increased when Moexipril is combined with Mesalazine.
MesalazineMesalazine may decrease the antihypertensive activities of Moexipril.
MetamizoleThe risk or severity of adverse effects can be increased when Moexipril is combined with Metamizole.
MethadoneMoexipril may increase the QTc-prolonging activities of Methadone.
MethazolamideThe risk or severity of adverse effects can be increased when Moexipril is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Moexipril.
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Moexipril.
MethyclothiazideThe risk or severity of adverse effects can be increased when Moexipril is combined with Methyclothiazide.
MethyldopaMoexipril may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Moexipril.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Moexipril.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Moexipril.
MetipranololMoexipril may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Moexipril.
MetoprololMetoprolol may increase the hypotensive activities of Moexipril.
MibefradilMoexipril may increase the hypotensive activities of Mibefradil.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Moexipril.
MifepristoneMifepristone may increase the QTc-prolonging activities of Moexipril.
MinaprineMinaprine may increase the hypotensive activities of Moexipril.
MinoxidilMinoxidil may increase the hypotensive activities of Moexipril.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Moexipril.
MoclobemideMoclobemide may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Moexipril.
MoxifloxacinMoexipril may increase the QTc-prolonging activities of Moxifloxacin.
MoxonidineMoexipril may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Moexipril is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Moexipril is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Nabumetone.
NadololMoexipril may increase the hypotensive activities of Nadolol.
NadroparinNadroparin may increase the hyperkalemic activities of Moexipril.
NaftifineThe risk or severity of adverse effects can be increased when Moexipril is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Moexipril is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Moexipril is combined with NCX 4016.
NebivololMoexipril may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Moexipril.
NepafenacThe risk or severity of adverse effects can be increased when Moexipril is combined with Nepafenac.
NesiritideThe risk or severity of adverse effects can be increased when Moexipril is combined with Nesiritide.
NialamideNialamide may increase the hypotensive activities of Moexipril.
NicardipineNicardipine may increase the hypotensive activities of Moexipril.
NicorandilNicorandil may increase the hypotensive activities of Moexipril.
NifedipineThe risk or severity of adverse effects can be increased when Moexipril is combined with Nifedipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Moexipril is combined with Niflumic Acid.
NiguldipineMoexipril may increase the hypotensive activities of Niguldipine.
NilotinibMoexipril may increase the QTc-prolonging activities of Nilotinib.
NilvadipineMoexipril may increase the hypotensive activities of Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Moexipril is combined with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Moexipril.
NisoldipineNisoldipine may increase the hypotensive activities of Moexipril.
NitrendipineMoexipril may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Moexipril is combined with Nitroglycerin.
NitroprussideNitroprusside may increase the hypotensive activities of Moexipril.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Moexipril.
ObinutuzumabMoexipril may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Moexipril.
OfloxacinMoexipril may increase the QTc-prolonging activities of Ofloxacin.
OlmesartanOlmesartan may increase the hypotensive activities of Moexipril.
OlopatadineThe risk or severity of adverse effects can be increased when Moexipril is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Moexipril is combined with Olsalazine.
OmapatrilatMoexipril may increase the hypotensive activities of Omapatrilat.
OndansetronMoexipril may increase the QTc-prolonging activities of Ondansetron.
OrgoteinThe risk or severity of adverse effects can be increased when Moexipril is combined with Orgotein.
OxaprozinThe risk or severity of adverse effects can be increased when Moexipril is combined with Oxaprozin.
OxprenololMoexipril may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Oxyphenbutazone.
PaliperidoneMoexipril may increase the QTc-prolonging activities of Paliperidone.
PanobinostatMoexipril may increase the QTc-prolonging activities of Panobinostat.
PapaverineThe risk or severity of adverse effects can be increased when Moexipril is combined with Papaverine.
ParecoxibThe risk or severity of adverse effects can be increased when Moexipril is combined with Parecoxib.
PargylineMoexipril may increase the hypotensive activities of Pargyline.
ParnaparinParnaparin may increase the hyperkalemic activities of Moexipril.
PazopanibMoexipril may increase the QTc-prolonging activities of Pazopanib.
PenbutololMoexipril may increase the hypotensive activities of Penbutolol.
PentamidineMoexipril may increase the QTc-prolonging activities of Pentamidine.
PentobarbitalPentobarbital may increase the hypotensive activities of Moexipril.
PentoliniumMoexipril may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Moexipril.
PerflutrenMoexipril may increase the QTc-prolonging activities of Perflutren.
PerindoprilMoexipril may increase the hypotensive activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Moexipril is combined with Pethidine.
PhenelzinePhenelzine may increase the hypotensive activities of Moexipril.
PheniprazinePheniprazine may increase the hypotensive activities of Moexipril.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Moexipril.
PhenoxybenzamineMoexipril may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Moexipril.
PhentolamineMoexipril may increase the hypotensive activities of Phentolamine.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Phenylbutazone.
PimecrolimusThe risk or severity of adverse effects can be increased when Moexipril is combined with Pimecrolimus.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Moexipril.
PinacidilMoexipril may increase the hypotensive activities of Pinacidil.
PindololMoexipril may increase the hypotensive activities of Pindolol.
PiretanidePiretanide may increase the hypotensive activities of Moexipril.
PirfenidoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Moexipril.
PiroxicamThe risk or severity of adverse effects can be increased when Moexipril is combined with Piroxicam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Moexipril.
PolythiazideMoexipril may increase the hypotensive activities of Polythiazide.
PrazosinPrazosin may increase the hypotensive activities of Moexipril.
PregabalinThe risk or severity of adverse effects can be increased when Moexipril is combined with Pregabalin.
PrimaquineMoexipril may increase the QTc-prolonging activities of Primaquine.
PrimidonePrimidone may increase the hypotensive activities of Moexipril.
ProcainamideMoexipril may increase the QTc-prolonging activities of Procainamide.
PromazineMoexipril may increase the QTc-prolonging activities of Promazine.
PropacetamolThe risk or severity of adverse effects can be increased when Moexipril is combined with Propacetamol.
PropafenoneMoexipril may increase the QTc-prolonging activities of Propafenone.
PropranololPropranolol may increase the hypotensive activities of Moexipril.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Moexipril.
PTC299The risk or severity of adverse effects can be increased when Moexipril is combined with PTC299.
QuetiapineThe risk or severity of adverse effects can be increased when Moexipril is combined with Quetiapine.
QuinaprilMoexipril may increase the hypotensive activities of Quinapril.
QuinethazoneQuinethazone may increase the hypotensive activities of Moexipril.
QuinidineMoexipril may increase the QTc-prolonging activities of Quinidine.
QuinineQuinine may increase the hypotensive activities of Moexipril.
QuinineMoexipril may increase the QTc-prolonging activities of Quinine.
RamiprilRamipril may increase the hypotensive activities of Moexipril.
RasagilineRasagiline may increase the hypotensive activities of Moexipril.
RemikirenRemikiren may increase the hypotensive activities of Moexipril.
RescinnamineMoexipril may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Moexipril.
ResveratrolThe risk or severity of adverse effects can be increased when Moexipril is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Moexipril.
RiociguatMoexipril may increase the hypotensive activities of Riociguat.
RisperidoneMoexipril may increase the hypotensive activities of Risperidone.
RituximabMoexipril may increase the hypotensive activities of Rituximab.
RofecoxibThe risk or severity of adverse effects can be increased when Moexipril is combined with Rofecoxib.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Moexipril.
SacubitrilThe risk or severity of adverse effects can be increased when Moexipril is combined with Sacubitril.
SafrazineSafrazine may increase the hypotensive activities of Moexipril.
SalicylamideThe risk or severity of adverse effects can be increased when Moexipril is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Moexipril is combined with Salicylic acid.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Moexipril.
SalsalateThe risk or severity of adverse effects can be increased when Moexipril is combined with Salsalate.
SaprisartanMoexipril may increase the hypotensive activities of Saprisartan.
SaquinavirMoexipril may increase the QTc-prolonging activities of Saquinavir.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Moexipril.
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Moexipril.
SecobarbitalSecobarbital may increase the hypotensive activities of Moexipril.
SelegilineSelegiline may increase the hypotensive activities of Moexipril.
SelexipagMoexipril may increase the hypotensive activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Moexipril is combined with Seratrodast.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Moexipril.
SildenafilSildenafil may increase the antihypertensive activities of Moexipril.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Moexipril.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Moexipril.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Moexipril.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Moexipril.
SitaxentanMoexipril may increase the hypotensive activities of Sitaxentan.
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Moexipril is combined with Sodium aurothiomalate.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Moexipril.
SpiraprilMoexipril may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Moexipril.
SRT501The risk or severity of adverse effects can be increased when Moexipril is combined with SRT501.
St. John's WortThe metabolism of Moexipril can be increased when combined with St. John's Wort.
SulfasalazineThe risk or severity of adverse effects can be increased when Moexipril is combined with Sulfasalazine.
SulfisoxazoleMoexipril may increase the QTc-prolonging activities of Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Moexipril is combined with Sulindac.
SuprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Suprofen.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Moexipril.
TadalafilTadalafil may increase the antihypertensive activities of Moexipril.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Moexipril.
TelavancinMoexipril may increase the QTc-prolonging activities of Telavancin.
TelithromycinMoexipril may increase the QTc-prolonging activities of Telithromycin.
TelmisartanMoexipril may increase the hypotensive activities of Telmisartan.
TemocaprilMoexipril may increase the hypotensive activities of Temocapril.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Moexipril.
TenoxicamThe risk or severity of adverse effects can be increased when Moexipril is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Moexipril is combined with Tepoxalin.
TerazosinThe risk or severity of adverse effects can be increased when Moexipril is combined with Terazosin.
TeriflunomideThe risk or severity of adverse effects can be increased when Moexipril is combined with Teriflunomide.
TerlipressinMoexipril may increase the hypotensive activities of Terlipressin.
TetrabenazineMoexipril may increase the QTc-prolonging activities of Tetrabenazine.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Moexipril.
ThiamylalThiamylal may increase the hypotensive activities of Moexipril.
ThiopentalThiopental may increase the hypotensive activities of Moexipril.
ThioridazineMoexipril may increase the QTc-prolonging activities of Thioridazine.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Moexipril.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Moexipril is combined with Tiaprofenic acid.
TiboloneMoexipril may increase the hypotensive activities of Tibolone.
TicrynafenMoexipril may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Moexipril.
TinzaparinTinzaparin may increase the hyperkalemic activities of Moexipril.
TipranavirThe serum concentration of Moexipril can be decreased when it is combined with Tipranavir.
TizanidineTizanidine may increase the hypotensive activities of Moexipril.
TizanidineThe risk or severity of adverse effects can be increased when Moexipril is combined with Tizanidine.
TolazolineMoexipril may increase the hypotensive activities of Tolazoline.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Moexipril is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Moexipril is combined with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Moexipril.
TolvaptanTolvaptan may increase the hyperkalemic activities of Moexipril.
TorasemideTorasemide may increase the hypotensive activities of Moexipril.
ToremifeneMoexipril may increase the QTc-prolonging activities of Toremifene.
TrandolaprilTrandolapril may increase the hypotensive activities of Moexipril.
TranilastThe risk or severity of adverse effects can be increased when Moexipril is combined with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Moexipril.
TranylcypromineTranylcypromine may increase the hypotensive activities of Moexipril.
TravoprostTravoprost may increase the hypotensive activities of Moexipril.
TreprostinilTreprostinil may increase the hypotensive activities of Moexipril.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Moexipril.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Moexipril.
TrichlormethiazideMoexipril may increase the hypotensive activities of Trichlormethiazide.
TrimazosinMoexipril may increase the hypotensive activities of Trimazosin.
TrimethaphanMoexipril may increase the hypotensive activities of Trimethaphan.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Moexipril.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Moexipril.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Moexipril is combined with Trisalicylate-choline.
UdenafilUdenafil may increase the antihypertensive activities of Moexipril.
UnoprostoneMoexipril may increase the hypotensive activities of Unoprostone.
ValdecoxibThe risk or severity of adverse effects can be increased when Moexipril is combined with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Moexipril.
VandetanibMoexipril may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the antihypertensive activities of Moexipril.
VemurafenibMoexipril may increase the QTc-prolonging activities of Vemurafenib.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Moexipril.
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Moexipril.
XylometazolineMoexipril may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Moexipril.
ZaltoprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Zaltoprofen.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Moexipril.
ZileutonThe risk or severity of adverse effects can be increased when Moexipril is combined with Zileuton.
ZiprasidoneMoexipril may increase the QTc-prolonging activities of Ziprasidone.
ZomepiracThe risk or severity of adverse effects can be increased when Moexipril is combined with Zomepirac.
ZuclopenthixolMoexipril may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Herbs that may attenuate the antihypertensive effect of moexipril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of moexipril.
  • Moexipril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.
  • Take moexipril one hour before or two hours after meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Chrysant SG, Chrysant GS: Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol. 2004 Aug;44(8):827-36. [PubMed:15286086 ]
  3. Edling O, Bao G, Feelisch M, Unger T, Gohlke P: Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther. 1995 Nov;275(2):854-63. [PubMed:7473177 ]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Carboxypeptidase which converts angiotensin I to angiotensin 1-9, a peptide of unknown function, and angiotensin II to angiotensin 1-7, a vasodilator. Also able to hydrolyze apelin-13 and dynorphin-13 with high efficiency. May be an important regulator of heart function.(Microbial infection) Acts as a receptor for SARS coronavirus/SARS-CoV and human coronavirus NL63/HCoV-NL63.
Gene Name:
ACE2
Uniprot ID:
Q9BYF1
Molecular Weight:
92462.4 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Chrysant SG, Chrysant GS: Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol. 2004 Aug;44(8):827-36. [PubMed:15286086 ]
  3. Edling O, Bao G, Feelisch M, Unger T, Gohlke P: Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther. 1995 Nov;275(2):854-63. [PubMed:7473177 ]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23